Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival

Michael J. Fisch, Kelly L. Howard, Lawrence Einhorn, George W. Sledge

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Platinum-DNA adducts can be measured in peripheral blood leukocytes during platinum-based chemotherapy, and high adduct levels have been correlated with favorable clinical response in patients with germ cell cancer. Twenty-five patients with advanced germ cell cancer were treated with platinum-based chemotherapy regimens using the same dose and schedule of cisplatin. Platinum-DNA adducts were measured by atomic absorption spectrometry on the first and fifth days of the first cycle of cisplatin-based therapy. The patients were followed prospectively for 6-35 months (median, 26 months). Twenty-two patients had adduct levels measured 24 h after the first dose of cisplatin. There was no difference in the mean adduct levels of those who were alive and without progression of disease compared to those who were dead or progressing (P = 0.65). Twenty-three patients had day 5 adduct levels measured. The mean day 5 adduct level in the 15 patients who were alive and without progression was 62.133 fmol/μg, compared to 153.50 fmol/μg in the patients who were dead or progressing (two-sided P = 0.02). Contrary to previous reports, these data indicate that high platinum-DNA adduct levels do not correlate with favorable outcome in patients with advanced germ cell cancer.

Original languageEnglish
Pages (from-to)1063-1066
Number of pages4
JournalClinical Cancer Research
Volume2
Issue number6
StatePublished - Jun 1996

Fingerprint

DNA Adducts
Germ Cell and Embryonal Neoplasms
Platinum
Cell Survival
Leukocytes
Cisplatin
Drug Therapy
Disease Progression
Spectrum Analysis
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. / Fisch, Michael J.; Howard, Kelly L.; Einhorn, Lawrence; Sledge, George W.

In: Clinical Cancer Research, Vol. 2, No. 6, 06.1996, p. 1063-1066.

Research output: Contribution to journalArticle

@article{d2f36083cae1494ba6f25077a56fd069,
title = "Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival",
abstract = "Platinum-DNA adducts can be measured in peripheral blood leukocytes during platinum-based chemotherapy, and high adduct levels have been correlated with favorable clinical response in patients with germ cell cancer. Twenty-five patients with advanced germ cell cancer were treated with platinum-based chemotherapy regimens using the same dose and schedule of cisplatin. Platinum-DNA adducts were measured by atomic absorption spectrometry on the first and fifth days of the first cycle of cisplatin-based therapy. The patients were followed prospectively for 6-35 months (median, 26 months). Twenty-two patients had adduct levels measured 24 h after the first dose of cisplatin. There was no difference in the mean adduct levels of those who were alive and without progression of disease compared to those who were dead or progressing (P = 0.65). Twenty-three patients had day 5 adduct levels measured. The mean day 5 adduct level in the 15 patients who were alive and without progression was 62.133 fmol/μg, compared to 153.50 fmol/μg in the patients who were dead or progressing (two-sided P = 0.02). Contrary to previous reports, these data indicate that high platinum-DNA adduct levels do not correlate with favorable outcome in patients with advanced germ cell cancer.",
author = "Fisch, {Michael J.} and Howard, {Kelly L.} and Lawrence Einhorn and Sledge, {George W.}",
year = "1996",
month = "6",
language = "English",
volume = "2",
pages = "1063--1066",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival

AU - Fisch, Michael J.

AU - Howard, Kelly L.

AU - Einhorn, Lawrence

AU - Sledge, George W.

PY - 1996/6

Y1 - 1996/6

N2 - Platinum-DNA adducts can be measured in peripheral blood leukocytes during platinum-based chemotherapy, and high adduct levels have been correlated with favorable clinical response in patients with germ cell cancer. Twenty-five patients with advanced germ cell cancer were treated with platinum-based chemotherapy regimens using the same dose and schedule of cisplatin. Platinum-DNA adducts were measured by atomic absorption spectrometry on the first and fifth days of the first cycle of cisplatin-based therapy. The patients were followed prospectively for 6-35 months (median, 26 months). Twenty-two patients had adduct levels measured 24 h after the first dose of cisplatin. There was no difference in the mean adduct levels of those who were alive and without progression of disease compared to those who were dead or progressing (P = 0.65). Twenty-three patients had day 5 adduct levels measured. The mean day 5 adduct level in the 15 patients who were alive and without progression was 62.133 fmol/μg, compared to 153.50 fmol/μg in the patients who were dead or progressing (two-sided P = 0.02). Contrary to previous reports, these data indicate that high platinum-DNA adduct levels do not correlate with favorable outcome in patients with advanced germ cell cancer.

AB - Platinum-DNA adducts can be measured in peripheral blood leukocytes during platinum-based chemotherapy, and high adduct levels have been correlated with favorable clinical response in patients with germ cell cancer. Twenty-five patients with advanced germ cell cancer were treated with platinum-based chemotherapy regimens using the same dose and schedule of cisplatin. Platinum-DNA adducts were measured by atomic absorption spectrometry on the first and fifth days of the first cycle of cisplatin-based therapy. The patients were followed prospectively for 6-35 months (median, 26 months). Twenty-two patients had adduct levels measured 24 h after the first dose of cisplatin. There was no difference in the mean adduct levels of those who were alive and without progression of disease compared to those who were dead or progressing (P = 0.65). Twenty-three patients had day 5 adduct levels measured. The mean day 5 adduct level in the 15 patients who were alive and without progression was 62.133 fmol/μg, compared to 153.50 fmol/μg in the patients who were dead or progressing (two-sided P = 0.02). Contrary to previous reports, these data indicate that high platinum-DNA adduct levels do not correlate with favorable outcome in patients with advanced germ cell cancer.

UR - http://www.scopus.com/inward/record.url?scp=0029974336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029974336&partnerID=8YFLogxK

M3 - Article

C2 - 9816268

AN - SCOPUS:0029974336

VL - 2

SP - 1063

EP - 1066

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -